Iterum Therapeutics (NASDAQ:ITRM) Rating Increased to Buy at ValuEngine

Iterum Therapeutics (NASDAQ:ITRM) was upgraded by equities researchers at ValuEngine from a “hold” rating to a “buy” rating in a research note issued to investors on Wednesday, ValuEngine reports.

Other equities research analysts have also issued research reports about the company. Royal Bank of Canada cut their target price on Iterum Therapeutics to $17.00 and set an “outperform” rating on the stock in a research report on Wednesday, May 15th. HC Wainwright reissued a “buy” rating and set a $17.00 target price on shares of Iterum Therapeutics in a research report on Thursday, August 15th. Finally, Zacks Investment Research raised Iterum Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 17th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $15.75.

Shares of ITRM traded down $0.19 during midday trading on Wednesday, hitting $6.51. The company had a trading volume of 30,305 shares, compared to its average volume of 10,045. The company’s 50-day simple moving average is $6.65 and its 200-day simple moving average is $6.85. The company has a debt-to-equity ratio of 0.44, a quick ratio of 2.10 and a current ratio of 2.10. The firm has a market capitalization of $90.87 million, a P/E ratio of -0.92 and a beta of 2.05. Iterum Therapeutics has a 1 year low of $4.70 and a 1 year high of $11.22.

Iterum Therapeutics (NASDAQ:ITRM) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($1.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.50) by ($0.43). Iterum Therapeutics had a negative net margin of 11,956.64% and a negative return on equity of 136.21%. Equities analysts predict that Iterum Therapeutics will post -6.74 earnings per share for the current fiscal year.

Iterum Therapeutics Company Profile

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.

See Also: Analyst Ratings

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with's FREE daily email newsletter.